Literature DB >> 24284092

The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer.

Hideo Fukuhara1, Keiji Inoue, Atsushi Kurabayashi, Mutsuo Furihata, Hirofumi Fujita, Kozo Utsumi, Junzo Sasaki, Taro Shuin.   

Abstract

BACKGROUND: The aim of this study was to clarify the mechanism of accumulation of 5-aminolevulinic acid (ALA)-dependent protoporphyrin IX (PpIX), ALA-photodynamic therapy (PDT)-induced cell death and enhanced efficiency by a ferrochelatase inhibitor in prostate cancer PC-3 cells.
METHODS: The accumulation of ALA-induced PpIX in PC-3 cells was observed by fluorescence microscopy and measured by flow cytometry analysis. The efficiency of ALA-PDT was analyzed by flow cytometry and assessed by cell death, caspase-3 activity and mitochondrial membrane potential. The ALA-PDT-promoting effects of ferrochelatase inhibitors, such as deferoxamine and NOC-18, were also analyzed. We confirmed the results obtained in vivo with an animal model using nude mice.
RESULTS: ALA-induced PpIX accumulation increased in time- and ALA concentration-dependent manners. ALA-PDT decreased the levels of mitochondrial membrane potential, and induced cell death occurred by both apoptosis and necrosis. Inhibition of ferrochelatase by deferoxamine and NOC-18 led to increase of PpIX accumulation and enhanced effect of ALA-PDT in PC-3 cells. In vivo, the degeneration of tumor tissue by ALA-PDT was observed within a broader range and led to apoptosis and necrosis.
CONCLUSION: This study demonstrated ALA-PDT induced PC-3 cell death by the mechanisms of both necrosis and apoptosis through a caspase-independent mitochondrial pathway. Inhibition of ferrochelatase enhanced these effects, suggesting that ferrochelatase played an important role in ALA-PDT. ALA-PDT could be a new modality for focal therapy of prostate cancer.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  1-hydroxy-2-oxo3,3-bis(2-aminoethyl)-1-triazene; 10-nonyl acridine orange; 5-Aminolevulinic acid; 5-aminolevulinic acid; ALA; BSA; DFX; FBS; Ferrochelatase; NAO; NOC-18; PDD; PDT; Photodynamic therapy; PpIX; Prostate cancer; Protoporphyrin IX; bovine serum albumin; deferoxamine; fetal bovine serum; photodynamic diagnosis; photodynamic therapy; protoporphyrin IX

Mesh:

Substances:

Year:  2013        PMID: 24284092     DOI: 10.1016/j.pdpdt.2013.03.003

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  11 in total

1.  Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine.

Authors:  Pratheeba Palasuberniam; Daniel Kraus; Matthew Mansi; Alexander Braun; Richard Howley; Kenneth A Myers; Bin Chen
Journal:  Photochem Photobiol       Date:  2019-03-15       Impact factor: 3.421

2.  Oligopeptide Transporter-1 is Associated with Fluorescence Intensity of 5-Aminolevulinic Acid-Based Photodynamic Diagnosis in Pancreatic Cancer Cells.

Authors:  Hidehito Kinoshita; Tsutomu Kanda; Tomoaki Takata; Takaaki Sugihara; Yukari Mae; Taro Yamashita; Takumi Onoyama; Yohei Takeda; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2020-06-12       Impact factor: 1.641

3.  Small-molecule inhibitors of ferrochelatase are antiangiogenic agents.

Authors:  Kamakshi Sishtla; Nathan Lambert-Cheatham; Bit Lee; Duk Hee Han; Jaehui Park; Sheik Pran Babu Sardar Pasha; Sanha Lee; Sangil Kwon; Anbukkarasi Muniyandi; Bomina Park; Noa Odell; Sydney Waller; Il Yeong Park; Soo Jae Lee; Seung-Yong Seo; Timothy W Corson
Journal:  Cell Chem Biol       Date:  2022-01-31       Impact factor: 9.039

Review 4.  Ferrochelatase: Mapping the Intersection of Iron and Porphyrin Metabolism in the Mitochondria.

Authors:  Chibuike David Obi; Tawhid Bhuiyan; Harry A Dailey; Amy E Medlock
Journal:  Front Cell Dev Biol       Date:  2022-05-12

Review 5.  Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement.

Authors:  Xue Yang; Pratheeba Palasuberniam; Daniel Kraus; Bin Chen
Journal:  Int J Mol Sci       Date:  2015-10-28       Impact factor: 5.923

Review 6.  Light-Induced Therapies for Prostate Cancer Treatment.

Authors:  Claudia Ferroni; Alberto Del Rio; Cecilia Martini; Elisabetta Manoni; Greta Varchi
Journal:  Front Chem       Date:  2019-10-29       Impact factor: 5.221

Review 7.  Molecular and Metabolic Mechanisms Underlying Selective 5-Aminolevulinic Acid-Induced Fluorescence in Gliomas.

Authors:  Jeffrey I Traylor; Mark N Pernik; Alex C Sternisha; Samuel K McBrayer; Kalil G Abdullah
Journal:  Cancers (Basel)       Date:  2021-02-02       Impact factor: 6.639

Review 8.  Current status of photodynamic technology for urothelial cancer.

Authors:  Keiji Inoue; Hideo Fukuhara; Shinkuro Yamamoto; Takashi Karashima; Atsushi Kurabayashi; Mutsuo Furihata; Kazuhiro Hanazaki; Hung Wei Lai; Shun-Ichiro Ogura
Journal:  Cancer Sci       Date:  2021-12-02       Impact factor: 6.716

9.  Performance of 5-aminolevulinic-acid-based photodynamic diagnosis for radical prostatectomy.

Authors:  Hideo Fukuhara; Keiji Inoue; Atsushi Kurabayashi; Mutsuo Furihata; Taro Shuin
Journal:  BMC Urol       Date:  2015-08-01       Impact factor: 2.264

10.  Photodynamic Antibiofilm and Antibacterial Activity of a New Gel with 5-Aminolevulinic Acid on Infected Titanium Surfaces.

Authors:  Morena Petrini; Silvia Di Lodovico; Giovanna Iezzi; Luigina Cellini; Domenico Tripodi; Adriano Piattelli; Simonetta D'Ercole
Journal:  Biomedicines       Date:  2022-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.